Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Diabetes 

Combining a GLP-1 receptor agonist plus insulin proves more effective than other diabetes therapies

A new study supports the use of GLP-1 agonists in combination with basal insulin in the management of patients with type 2 diabetes.

Patient measures his blood sugar levels with a blood glucose meter

Source: Ververidis Vasilis / Shutterstock.com

The meta-analysis included 15 studies that compared GLP-1 agonist and basal insulin combination therapy with other antidiabetic drugs in 4348 adults with type 2 diabetes

“A powerful and safer alternative to insulin” achieved robust glucose control for diabetes with no increased risk of hypoglycaemia or weight gain, conclude the authors of a systematic review of therapies published in The Lancet[1].

The combination of a glucagon-like peptide-1 receptor (GLP-1) agonist plus basal insulin offered the “ideal triumvirate”, according to Laura Young and John Buse from the University of North Carolina, USA, in an accompanying commentary to the meta-analysis[2].

The systematic review included 15 studies that compared GLP-1 agonist and basal insulin combination therapy with other antidiabetic drugs in 4,348 adults with type 2 diabetes.

The researchers, led by Ravi Retnakaran, from Mount Sinai Hospital, Toronto, Canada, noted that the high cost of both GLP-1 agonists and insulin analogues is likely to be the major barrier to widespread adoption of the treatment.

Combination therapy reduced glycated haemoglobin (HbA1c) by a mean of 0.44% more than other therapies and significantly improved the likelihood of achieving an HbA1c of 7.0% or lower, with a relative risk (RR) of 1.92. Furthermore, combination therapy was associated with a mean 3.22 kg reduction in body weight and did not increase the risk of hypoglycaemia (RR 0.99) versus other therapies.

Compared with full basal-bolus insulin regimens, the combination of GLP-1 agonist plus insulin resulted in a marginal 0.1% reduction in HbA1c, a 33% lower risk of hypoglycaemia and a mean 5.66-kg reduction in weight.

Retnakaran and colleagues say their data indicate that combining a GLP-1 agonist with basal insulin “can achieve the ideal triumvirate of short-term outcomes in diabetes management: potent glucose-lowering capacity without increased hypoglycaemia or weight gain”.

“Our findings clearly lend support to the use of GLP-1 agonists in combination with basal insulin in the clinical management of patients with type 2 diabetes.”

Victoria Ruszala, a diabetes pharmacist at North Bristol NHS Trust, said that the study provided reassurance about the co-prescription of GLP-1 agonists and basal insulin, already widely practised and endorsed by expert bodies such as the Association of British Clinical Diabetologists.

Ruszala added that while the meta-analysis summarised the overall benefits of combination therapy, there are likely to be differences in the efficacy and side-effects associated with individual GLP-1 agonists.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066519

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Pharmacy OSCEs

    Pharmacy OSCEs

    The only pharmacy-specific OSCE revision guide. This easy-to-use book covers the key competencies that will be tested in your exams.

    £25.00Buy now
  • Physicochemical Principles of Pharmacy

    Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Handbook of Pharmaceutical Excipients

    Handbook of Pharmaceutical Excipients

    The Handbook of Pharmaceutical Excipients contains essential data on the physical properties of excipients, their safe use and potential toxicity.

    £415.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.